World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
41661
World Ranking
12007
National Ranking
35

Overview

Wee Joo Chng is affiliated with the National University of Singapore in Singapore. Their research spans significant contributions within the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on subfields such as Molecular Biology, Hematology, Oncology, Pathology and Forensic Medicine, and Genetics.

The scientist's work addresses critical topics including:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Lymphoma Diagnosis and Treatment
  • RNA modifications and cancer
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research

Wee Joo Chng has frequently published in key venues within hematological and oncological research, such as:

  • Blood
  • Cancer Research
  • Clinical Lymphoma Myeloma & Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood Cancer Journal

Some of their recent papers reflect developments in classification and treatment strategies in hematolymphoid tumors, as well as enabling technologies for precision medicine. Notable publications include:

  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022, Leukemia)
  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022, Leukemia)
  • Enabling Technologies for Personalized and Precision Medicine (2020, Trends in biotechnology)
  • Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore (2021, Nature Biotechnology)
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021, The Lancet Oncology)

The scientist has established frequent collaborations with other researchers including Sanjay De Mel, Melissa Ooi, Cinnie Yentia Soekojo, Anand D. Jeyasekharan, and Chandramouli Nagarajan, reflecting a network of coauthors contributing to fields related to hematology and oncology.

Best Publications

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

    Jonathan J. Keats;Rafael Fonseca;Marta Chesi;Roelandt Schop

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

    King Pan Ng;Axel M Hillmer;Charles T H Chuah;Charles T H Chuah;Wen Chun Juan

  • IMWG consensus on risk stratification in multiple myeloma

    W J Chng;A Dispenzieri;C-S Chim;R Fonseca

  • Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

    George Mulligan;Constantine Mitsiades;Barb Bryant;Fenghuang Zhan

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Genetic aberrations and survival in plasma cell leukemia.

    R E Tiedemann;N Gonzalez-Paz;R A Kyle;R Santana-Davila

  • AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies

    Marta Chesi;Davide F. Robbiani;Michael Sebag;Wee Joo Chng

  • Telomerase directly regulates NF-κB-dependent transcription

    Arkasubhra Ghosh;Gaye Saginc;Shi Chi Leow;Ekta Khattar

  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Meletios A. Dimopoulos;Hartmut Goldschmidt;Ruben Niesvizky;Douglas Joshua

  • P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

    Xiao-Lan Li;Jianbiao Zhou;Zhi-Rong Chen;Wee-Joo Chng

  • A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

    Seok Jin Kim;Dok Hyun Yoon;Arnaud Jaccard;Wee Joo Chng

  • Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

    Wee J. Chng;Shaji Kumar;Scott VanWier;Greg Ahmann

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Management of treatment-emergent peripheral neuropathy in multiple myeloma

    P G Richardson;Michel Delforge;M Beksac;P Wen

  • Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

    WJ Chng;GF Huang;TH Chung;SB Ng

  • New Drugs and Novel Mechanisms of Action in Multiple Myeloma in 2013: A Report From the International Myeloma Working Group (IMWG)

    E. M. Ocio;P. G. Richardson;S. V. Rajkumar;A. Palumbo

Frequent Co-Authors

Rafael Fonseca
Rafael Fonseca Mayo Clinic
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Shaji Kumar
Shaji Kumar Mayo Clinic
Morie A. Gertz
Morie A. Gertz Mayo Clinic
Brian G.M. Durie
Brian G.M. Durie Cedars-Sinai Medical Center
Philip R. Greipp
Philip R. Greipp Mayo Clinic
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Robert A. Kyle
Robert A. Kyle Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA doesn’t always mean following the traditional MD route. Many students choose alternative online degrees that offer flexibility, affordability, and direct entry opportunities into the healthcare industry. For registered nurses looking to advance their qualifications, affordable rn to bsn programs can be a smart option, helping RNs earn their bachelor’s degree while working.

Those with a non-nursing background may consider entry level msn programs online, which provide a direct pathway to a master’s in nursing without the need for a prior nursing degree. Similarly, students searching for accessible admissions can explore direct entry nursing programs that typically have less competitive requirements and help accelerate entry into the profession.

Not all medical careers require years of clinical training. Many are drawn to healthcare support roles such as medical billing and coding. Fully online programs make it easier to get started, especially through online medical billing and coding schools that accept fafsa, which may reduce financial barriers with federal aid.

Best Scientists Citing Wee Joo Chng

Trending Scientists